Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 7,501 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Cancer Clear all
Not yet recruiting Not applicable Interventional

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma

NCT07110233
View directory record Official record
Conditions
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable
Interventions
TheraSphere® Yttrium-90 microspheres, Health Related Quality of Life Questionnaires (HRQOL)
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer

NCT00023933
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
iodine I 131 monoclonal antibody CC49-deltaCH2
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Phase 1Phase 2 Interventional

Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology

NCT05664178
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Tele-Resistance Training
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 22, 2026, 5:23 AM EDT
Not yet recruiting Phase 2 Interventional

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

NCT06855225
View directory record Official record
Conditions
Combined Hepatocellular and Cholangiocarcinoma
Interventions
Tremelimumab, Durvalumab, Gemcitabine, Cisplatin
Drug
Lead sponsor
Mehmet Akce
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Atorvastatin ± Aspirin in Lynch Syndrome Syndrome

NCT04379999
View directory record Official record
Conditions
Lynch Syndrome
Interventions
Atorvastatin 20mg, Atorvastatin 20mg AND Aspirin 325 mg
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

NCT00061932
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
Interventions
bortezomib, irinotecan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 22, 2026, 5:23 AM EDT
Terminated Phase 2 Interventional Results available

Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma

NCT02319304
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}, Low dose fractionated radiation therapy (LDFRT)
Drug · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 5:23 AM EDT
Withdrawn Not applicable Interventional

Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures

NCT02366858
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
19 gauge, 22 gauge
Procedure
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Phase 3 Interventional

Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

NCT00061815
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, oxaliplatin, leucovorin, 5-fluorouracil
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
39
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Fountain Valley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2010 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Not applicable Interventional

Outpatient Oncology Aromatherapy for Symptom Management

NCT04449315
View directory record Official record
Conditions
Anxiety, Nausea
Interventions
Young Living Lavender Essential Oil
Other
Lead sponsor
Central DuPage Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winfield, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 22, 2026, 5:23 AM EDT
Not listed Phase 2Phase 3 Interventional Results available

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

NCT01515787
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery, magnetic resonance imaging or endorectal ultrasound
Drug · Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1048
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 613 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 22, 2026, 5:23 AM EDT
Terminated Phase 3 Interventional

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

NCT01009593
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Carcinoma, Hepatocellular, Liver Diseases, Neoplasms by Histologic Type, Digestive System Neoplasms, Carcinoma, Liver Neoplasms, Neoplasms, Neoplasms by Site, Digestive System Diseases, Adenocarcinoma, Neoplasms, Glandular and Epithelial
Interventions
ABT-869, Sorafenib
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Beverly Hills, California • LaVerne, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Early Phase 1 Interventional

Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation

NCT00314743
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Ondansetron, Dexamethasone, Aprepitant
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer

NCT00098787
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, fluorouracil, irinotecan hydrochloride, leucovorin calcium, Oxaliplatin
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
110
States / cities
Greenbrae, California • Aurora, Colorado • Boulder, Colorado + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

NCT00137852
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Cisplatin, Irinotecan, Celecoxib, Radiation Therapy, Esophagectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

IACS-010759 in Advanced Cancers

NCT03291938
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Pancreatic Ductal Adenocarcinoma, Progesterone Receptor Negative, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Lymphoma, Refractory Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
Interventions
Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacodynamic Study, Pharmacokinetic Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 22, 2026, 5:23 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

NCT04486378
View directory record Official record
Conditions
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Interventions
RO7198457 intravenous (IV), Observational group (no intervention)
Drug · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Greenbrae, California • Indianapolis, Indiana • Minneapolis, Minnesota + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

NCT02442414
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
KBP-5209
Drug
Lead sponsor
Sihuan Pharmaceutical Holdings Group Ltd.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Indianapolis, Indiana • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 22, 2026, 5:23 AM EDT
Completed No phase listed Observational

Epidemiology of Barrett's Esophagus: A Population Based Study

NCT01286155
View directory record Official record
Conditions
Barrett's Esophagus, Gastroesophageal Reflux Disease (GERD), Olmsted County Resident
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 22, 2026, 5:23 AM EDT
Recruiting Not applicable Interventional

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

NCT07436078
View directory record Official record
Conditions
Female Breast Cancer, Prostate Cancer, Colorectal Carcinoma
Interventions
Culturally adapted Online Genetic Counseling and Testing Information
Behavioral
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
20 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 22, 2026, 5:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

NCT05194293
View directory record Official record
Conditions
Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Interventions
Durvalumab, Regorafenib
Biological · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

NCT02689284
View directory record Official record
Conditions
Gastric Cancer, Stomach Cancer, Esophageal Cancer
Interventions
Margetuximab 10 mg/kg, Margetuximab 15 mg, Pembrolizumab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
11
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 22, 2026, 5:23 AM EDT
Terminated Phase 1 Interventional

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

NCT04596033
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma, Small-cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Merkel Cell Carcinoma
Interventions
GEN-011, IL-2, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 22, 2026, 5:23 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

NCT05497778
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Gemcitabine, Nab paclitaxel, IM156
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 5:23 AM EDT